Last $5.78 USD
Change Today -0.09 / -1.53%
Volume 3.2M
OREX On Other Exchanges
Symbol
Exchange
NASDAQ GS
As of 8:10 PM 11/25/14 All times are local (Market data is delayed by at least 15 minutes).

orexigen therapeutics inc (OREX) Snapshot

Open
$5.90
Previous Close
$5.87
Day High
$6.00
Day Low
$5.76
52 Week High
03/19/14 - $7.82
52 Week Low
10/13/14 - $3.11
Market Cap
711.9M
Average Volume 10 Days
4.3M
EPS TTM
$-0.56
Shares Outstanding
123.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for OREXIGEN THERAPEUTICS INC (OREX)

orexigen therapeutics inc (OREX) Related Businessweek News

View More BusinessWeek News

orexigen therapeutics inc (OREX) Details

Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its product candidates include NB32, which has completed Phase III clinical trials and is being studied in a cardiovascular outcomes trial; and Empatic that has completed Phase II clinical trials. Orexigen Therapeutics, Inc. has collaboration agreement with Takeda Pharmaceutical Company Limited to develop and commercialize NB32 in the United States, Canada, and Mexico. The company was founded in 2002 and is headquartered in La Jolla, California.

50 Employees
Last Reported Date: 03/13/14
Founded in 2002

orexigen therapeutics inc (OREX) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $625.0K
Acting Chief Financial Officer, Principal Acc...
Total Annual Compensation: $370.0K
Senior Vice President, General Counsel and Se...
Total Annual Compensation: $370.0K
Head of Global Contrave Program and Senior Vi...
Total Annual Compensation: $370.0K
Chief Commercial Officer
Total Annual Compensation: $296.0K
Compensation as of Fiscal Year 2013.

orexigen therapeutics inc (OREX) Key Developments

Orexigen Therapeutics, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014

Orexigen Therapeutics, Inc. Presents at Brean Capital Life Sciences Summit, Nov-24-2014 . Venue: Convene (Formerly Sentry Centers), 730 3rd Avenue, New York, New York, United States.

Orexigen Therapeutics, Inc. Announces Unaudited Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014

Orexigen Therapeutics, Inc. announced unaudited earnings results for the third quarter and nine months ended September 30, 2014. For the third quarter, the company reported a net income of $11.273 million, or $0.09 per basic and diluted share, as compared to a net loss of $18.572 million, or $0.19 per basic and diluted share a year ago. Total revenues were $30.857 million against $0.857 million a year ago. This increase in Revenue was due to recognition of two regulatory/development milestones in Takeda partnership, consisting of $20 million upon regulatory approval in the United States and $10 million upon the delivery of launch supplies to Takeda. Income from operations was $13.041 million against loss from operations of $18.851 million a year ago. For the nine months, the company reported a net loss of $38.132 million, or $0.33 per basic and diluted share, as compared to a net loss of $56.186 million, or $0.59 per basic and diluted share a year ago. Total revenues were $32.571 million against $2.571 million a year ago. Loss from operations was $32.915 million against loss from operations of $56.242 million a year ago.

Orexigen Therapeutics, Inc. to Report Q3, 2014 Results on Nov 10, 2014

Orexigen Therapeutics, Inc. announced that they will report Q3, 2014 results at 8:30 AM, US Eastern Standard Time on Nov 10, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
OREX:US $5.78 USD 0.00

OREX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for OREX.
View Industry Companies
 

Industry Analysis

OREX

Industry Average

Valuation OREX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 21.5x
Price/Book 42.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 15.6x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OREXIGEN THERAPEUTICS INC, please visit www.orexigen.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.